Pasithea Capital Stock from 2010 to 2025

KTTAW Stock  USD 0.02  0  9.89%   
Pasithea Therapeutics Capital Stock yearly trend continues to be fairly stable with very little volatility. Capital Stock will likely drop to 88.92 in 2025. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
93.6
Current Value
88.92
Quarterly Volatility
6.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 783 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.44. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Pasithea Therapeutics' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Pasithea Therapeutics Corp over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Pasithea Therapeutics' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
   Capital Stock   
       Timeline  

Pasithea Capital Stock Regression Statistics

Arithmetic Mean12,517
Geometric Mean5,920
Coefficient Of Variation49.85
Mean Deviation4,658
Median14,938
Standard Deviation6,240
Sample Variance38.9M
Range17.9K
R-Value(0.60)
Mean Square Error26.8M
R-Squared0.36
Significance0.01
Slope(782.68)
Total Sum of Squares584M

Pasithea Capital Stock History

2025 88.92
2024 93.6
2023 104.0
202218 K
202117.7 K

Other Fundumenentals of Pasithea Therapeutics

Pasithea Therapeutics Capital Stock component correlations

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Capital Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Stock 93.60  88.92 
Issuance Of Capital Stock24.4 M31 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.